Track market-moving stories before they get noisy

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds GoDaddy Inc. (“GoDaddy” or the “Company”) (NYSE: GDDY) of the October 20, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.

Should You Join The GoDaddy Class Action Lawsuit:

Do you, or did you, own shares of GoDaddy Inc. (NYSE: GDDY)?Did you purchase your shares between September 3, 2025 and February 24, 2026, inclusive?Did you lose money in your investment in GoDaddy Inc.?
What To Do Next:

Investors are encouraged to act promptly and submit a form at GoDaddy Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].

If you wish to serve as lead plaintiff for the Class, you must file papers by October 20, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About The Lawsuit:

A lawsuit was filed on behalf of investors (the “Class”) who purchased or acquired the common stock of GoDaddy between September 3, 2025 and February 24, 2026, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.

The lawsuit alleges that defendants made materially false and misleading statements and omissions regarding the Company’s business operations, growth prospects, and financial stability. As a result of these alleged misrepresentations, GoDaddy common stock traded at artificially inflated prices during the Class Period. When the truth was disclosed, investors allegedly suffered significant losses.

About Bernstein Liebhard:

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
[email protected]

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in GoDaddy Inc. (NYSE: GDDY) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between September 3, 2025 and February 24, 2026. Find out if you could qualify to recover your losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

GDDY shares fell from $92.30 to $79.12, a decline of $13.18 per share, or more than 14%, on heavier than usual trading volume. Full year 2025 total bookings growth came in at 7%, below the 8% figure previously communicated to investors. Applications to serve as lead plaintiff must be filed by October 20, 2026.

The Alleged $4.99 Domain Discount Methodology

At the center of this domain pricing securities fraud action is a promotional price of $4.99 for one-year dotcom domain contracts, a figure well below the $10 to $20 per year typical of the multi-year contracts the Company had historically sold. According to the lawsuit, this promotion was introduced during the Class Period and was not disclosed to investors while it was underway. The complaint alleges the shift from typical three-year terms to one-year terms reduced upfront bookings and average order size.

How the Alleged Promotion Affected Reported Financials

The lawsuit contends that fourth quarter 2025 total bookings growth decelerated sharply to 5%, down from 9% in the prior quarter and below analyst estimates of 7%. The complaint alleges that investors purchasing during this window paid artificially inflated prices because the pricing shift driving that deceleration had not been disclosed.

Key Domain Pricing Allegations for Shareholders

A promotional price of $4.99 for one-year dotcom domains was allegedly introduced without contemporaneous disclosure to investorsTypical domain contracts had run $10 to $20 per year, often on three-year terms, according to the lawsuitThe complaint alleges the term-mix shift toward one-year contracts reduced upfront bookings and average order sizeFourth quarter total bookings growth allegedly decelerated to 5% from 9% the prior quarterFull year 2025 bookings growth allegedly finished at 7% rather than the 8% previously indicatedApplications and Commerce bookings growth also decelerated, the lawsuit contends, as domain discounting affected bundled products "This case presents important questions about pricing and promotion disclosure obligations in the internet services sector. The complaint alleges that a material change in domain contract terms was affecting bookings while investors were told a different story about the Company's discounting approach." -- Joseph E. Levi, Esq.

Submit your information here or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the GDDY Lawsuit

Q: What is the GDDY class action lawsuit about? A: A securities class action has been filed against GoDaddy Inc. (NYSE: GDDY) alleging materially false and misleading statements between September 3, 2025 and February 24, 2026. Shares fell approximately 14% after the Company disclosed a previously undisclosed $4.99 one-year dotcom domain promotion that reduced upfront bookings and average order size, alongside fourth quarter bookings growth of 5%. Investors who purchased shares during the Class Period and suffered losses may be eligible to seek compensation.

Q: Who is eligible to join the GDDY investor lawsuit? A: Investors who purchased GDDY stock or securities between September 3, 2025 and February 24, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What court was the GDDY class action filed in? A: The case was filed in the United States District Court for the Southern District of New York, governed by the Private Securities Litigation Reform Act of 1995.

Q: What do GDDY investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my GDDY shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/fractyl-health-inc-guts-class_action_lawsuit.

Fractyl Case Details

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:

(1) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort's clinical sites compromised the integrity of its efficacy results; 
(2) accordingly, Revita's clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort's ability to assess Revita's efficacy; and 
(3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

What's Next for Fractyl Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/fractyl-health-inc-guts-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Fractyl you have until October 20, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Fractyl Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Fractyl Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.

New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against GoDaddy Inc. ("GoDaddy" or the "Company") (NYSE: GDDY) on behalf of investors that purchased or otherwise acquired GoDaddy common stock between September 3, 2025 and February 24, 2026 (the "Class Period").

CLICK HERE TO JOIN THE CASE

If you are an investor in GoDaddy and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8566.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 20, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

The Complaint alleges that throughout the Class Period, the Defendants made false and misleading statements, and omitted information necessary to make the statements not false or misleading at the time they were made, because while the Company represented to investors that its strategy "isn't to grow customers just for the sake of growing customers" and that "[w]e've seen the average order size go up," the Company had implemented a promotion focusing on short term contracts with smaller valuations, which in turn led to a decrease in total bookings and deceleration of bookings growth for both the fourth quarter and full year 2025.

The Complaint further alleges that on February 24, 2026 after the close of the market, the truth regarding the Company's promotional discount instituted in the fall of 2025 and its material, adverse effect on total bookings growth was revealed when the Company issued a press release reporting its fourth quarter and full year 2025 financial results with the SEC on Form 8-K (the "Press Release"). The Press Release revealed that total bookings growth had sharply decelerated to 5% in the fourth quarter of 2025.

The Complaint alleges that these disclosures caused the price of GoDaddy common stock to decline from a price of $92.30 per share on Tuesday, February 24, 2026 to a closing price of $79.12 per share on Wednesday, February 25, 2026, a decline of $13.18 per share, or more than 14% on heavier than usual volume.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/godaddy-inc-investor-alert-learn-more-now/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313421

Source: Kaplan Fox & Kilsheimer LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - September 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GoDaddy Inc. (NYSE: GDDY) between September 3, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important October 20, 2026 lead plaintiff deadline

SO WHAT: If you purchased GoDaddy common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the GoDaddy class action, go to https://rosenlegal.com/cases/godaddy-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that while GoDaddy was telling investors that its strategy "isn't to grow customers just for the sake of growing customers" and that "[w]e've seen the average order size go up," GoDaddy had implemented a promotion that directly contradicted those representations by focusing on short term contracts with smaller valuations, which in turn led to a decrease in total bookings and deceleration of bookings growth for both the fourth quarter and full year 2025. In fact, when the truth was ultimately revealed, GoDaddy admitted that the promotion "reduced" the average order size, directly contradicting the representation that the average order size was going up. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the GoDaddy class action, go to https://rosenlegal.com/cases/godaddy-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313570

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Smith+Nephew announces cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030

LONDON, UK / ACCESS Newswire / September 8, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announces today an offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to U.S.$250 million aggregate principal amount (the "Maximum Tender Amount") of the Company's 2.032% Senior Notes due 2030 (the "Notes") from each registered holder of the Notes (each a "Holder" and collectively, the "Holders"). Capitalized terms not otherwise defined in this announcement have the same meaning as assigned to them in the Offer to Purchase.

Holders are advised to read carefully the Offer to Purchase for full details of, and information on the procedures for participating in, the Tender Offer. The following table sets forth certain information relating to pricing for the Tender Offer.

Title of Security

CUSIP/ISIN(1)

Aggregate Principal Amount

Outstanding

Reference U.S.

Treasury Security

Fixed Spread

(basis points)

Bloomberg

Reference Page(2)

Maximum

Tender Amount(3)

2.032% Senior

Notes due 2030

(Maturity date: October 14, 2030)

83192P AA6 / US83192PAA66

$900,000,000

4.375% U.S.

Treasury due August 31,

2031

55 bps

FIT1

$250,000,000

(1) No representation is made as to the correctness or accuracy of the CUSIP or ISIN numbers listed in this announcement or printed on the Notes. They are provided solely for convenience.

(2) The Bloomberg Reference Page is provided for convenience only. To the extent any Bloomberg Reference Page changes prior to the Price Determination Date (as defined in the Offer to Purchase), the Dealer Manager (as defined below) referred to below will quote the Reference Treasury Security from the updated Bloomberg Reference Page.

(3)The Company reserves the right to increase or decrease the Maximum Tender Amount by press release no later than the third business day before the Expiration Time (as defined below).

Purpose of the Tender Offer

The purpose of the Tender Offer together with the Concurrent Notes Offering (as defined below) is to proactively manage the Company's debt portfolio and to extend the average maturity profile of the Company's existing debt. Notes that are accepted and purchased in the Tender Offer will be canceled and will no longer remain outstanding obligations of the Company.

New Notes and Financing Condition

The Company announced on September 8, 2026 its intention, subject to market conditions, to issue senior notes due 2036 (the "New Notes") in the concurrent notes offering (the "Concurrent Notes Offering"). Whether the Company will accept for purchase any Notes validly tendered in the Tender Offer is subject to, and conditioned upon, satisfaction or, where applicable, waiver of, the Company receiving aggregate gross proceeds from the Concurrent Notes Offering at or prior to the Expiration Time in an amount that is sufficient to effect the repurchase of the Notes validly tendered and accepted for purchase pursuant to the Tender Offer, on terms satisfactory to the Company in its sole discretion (the "Financing Condition").

Allocation of New Notes

The Company intends, in connection with the allocation of the New Notes in the Concurrent Notes Offering, to consider among other factors whether or not the relevant investor seeking an allocation of the New Notes in the Concurrent Notes Offering has validly tendered or indicated to the Company or BofA Securities (the "Dealer Manager") a firm intention to tender any Notes it holds pursuant to the Tender Offer and, if so, the aggregate principal amount of such Notes tendered or indicated to be tendered by such investor. When determining allocations of the notes in the Concurrent Notes Offering, the Company intends to give some degree of preference to those investors who, prior to such allocation, have validly tendered Notes, or have indicated their firm intention to tender Notes, pursuant to the Tender Offer. However, the Company will consider various factors in making allocation decisions and is not obliged to allocate notes in the Concurrent Notes Offering to an investor who has validly tendered or indicated to the Company or the Dealer Manager a firm intention to tender any Notes it holds pursuant to the Tender Offer and if allocated, the amount may be less than the amount tendered and accepted.

Any potential allocation of New Notes in the Concurrent Notes Offering, while being considered by the Company as set out above, will be made in accordance with customary new issue allocation processes and procedures following the completion of the book building process for the Concurrent Notes Offering and will be made at the sole discretion of the Company. In the event that a holder validly tenders Notes pursuant to the Tender Offer, such Notes will remain subject to such tender and the conditions of the Tender Offer as set out in the Offer to Purchase irrespective of whether that holder receives all, part or none of any allocation of New Notes in the Concurrent Notes Offering for which it has applied.

Holders should note that the pricing and allocation of the New Notes are expected to take place prior to the Expiration Time for the Tender Offer and any holder that wishes to subscribe for New Notes in addition to tendering existing Notes for purchase pursuant to the Tender Offer should therefore provide, as soon as practicable, and prior to the New Notes allocation, to the Dealer Manager any indications that it has tendered or an indication of a firm intention to tender Notes for purchase pursuant to the Tender Offer and the quantum of Notes that it intends to tender. Please refer to the Offer to Purchase for further details.

Tender Offer Consideration and Accrued Interest

The consideration offered for each $1,000 principal amount of Notes subject to the Tender Offer validly tendered and not validly withdrawn at or prior to the Expiration Time and accepted for purchase will be the Tender Offer Consideration, which will be payable on the Settlement Date (as defined below). In no event will the Tender Offer Consideration be paid prior to the Expiration Time. The Tender Offer Consideration for the Notes will be determined at the Price Determination Date, expected to be 4:00 p.m., New York City time, on September 15, 2026, taking into account the maturity date of the Notes and shall be calculated in accordance with standard market practice as further described in the Offer to Purchase.

Holders will also receive accrued and unpaid interest thereon from the last interest payment date up to, but excluding, the date of payment of the Tender Offer Consideration, which is expected to be September 18, 2026.

Maximum Tender Amount and Proration

The aggregate principal amount of Notes purchased will not exceed U.S.$250 million. If the aggregate principal amount of Notes validly tendered and not validly withdrawn exceeds the Maximum Tender Amount, acceptance of the Notes will be subject to proration. The Company reserves the right to increase or decrease the Maximum Tender Amount by press release or other public announcement no later than 9:00 a.m., New York City time, on the third business day before the Expiration Time (unless amended).

If the aggregate principal amount of Notes validly tendered and not validly withdrawn would cause the Maximum Tender Amount to be exceeded, then the Tender Offer will be oversubscribed. In that case, the Notes accepted for purchase on the Settlement Date may be accepted on a prorated basis.

All Notes not accepted as a result of proration will be returned to the tendering Holder. A separate tender instruction must be submitted on behalf of each beneficial owner of the Notes, given the potential proration.

Offer Conditions

The Tender Offer is subject to the satisfaction or waiver of certain conditions described in the Offer to Purchase, including the Financing Condition.

Indicative Timetable

The following table sets out the expected dates and times of the key events relating to the Tender Offer. This is an indicative timetable and is subject to change.

Date

Calendar Date and Time

Launch Date

8-Sep-26

Withdrawal Rights

Tendered Notes may be validly withdrawn at any time (i) prior to the earlier of (x) the Expiration Time and (y) if the Tender Offer is extended, the tenth business day after commencement of the Tender Offer, and (ii) after the 60th business day after the commencement of the Tender Offer if for any reason the Tender Offer has not been consummated within 60 business days after commencement.

Price Determination Date

4:00 p.m., New York City time, on September 15, 2026, unless extended.

Expiration Time

5:00 p.m., New York City time, on September 15, 2026, unless extended or earlier terminated.

Results Announcement Date

As soon as practicable on the day following the Expiration Time, expected to be on September 16, 2026, unless extended by the Company.

Settlement Date

Promptly after the Expiration Time, expected to be September 18, 2026, assuming that the Tender Offer is not extended or earlier terminated.

Holders are advised to read carefully the Offer to Purchase for full details of and information on the procedures for participating in the Tender Offer.

Further Information

Holders may access the Offer to Purchase at https://gbsc-usa.com/smith&nephew/.

Questions and requests for assistance in connection with the Tender Offer may be directed to the Dealer Manager at:

Merrill Lynch International

2 King Edward Street London, EC1A 1HQ United Kingdom
Attn: Liability Management Group Telephone (Europe): +44 20 7996 5420
Telephone (U.S. Toll Free): +1 (888) 292-0070
Telephone (U.S.): +1 (980) 387-3907
Email: [email protected]

Questions and requests for assistance in connection with the tender of Notes including requests for a copy of the Offer to Purchase may be directed to:

Global Bondholder Services Corporation

65 Broadway - Suite 404 New York, New York 10006 Attn: Corporate Actions
Banks and Brokers Call: +1 (212) 430-3774
Toll Free: +1 (855) 654-2015
Email: [email protected]

NOTICE AND DISCLAIMER

From time to time, the Company may purchase additional Notes in the open market, in privately negotiated transactions, through tender offers or otherwise, or may redeem Notes pursuant to the terms of the indenture governing the Notes. Any future purchases or redemptions may be on the same terms or on terms that are more or less favorable to Holders of Notes than the terms of the Tender Offer. Any future purchases or redemptions by the Company will depend on various factors existing at that time. There can be no assurance as to which, if any, of these alternatives (or combinations thereof) the Company may choose to pursue in the future. The effect of any of these actions may directly or indirectly affect the price of any Notes that remain outstanding after the consummation or termination of the Tender Offer.

This announcement must be read in conjunction with the Offer to Purchase. This announcement and the Offer to Purchase contain important information which must be read carefully before any decision is made with respect to the Tender Offer. If any Holder is in any doubt as to the action it should take or is unsure of the impact of the Tender Offer, it is recommended to seek its own financial and legal advice, including as to any tax consequences, from its stockbroker, bank manager, attorney, accountant or other independent financial or legal adviser. Any individual or company whose Notes are held on its behalf by a broker, dealer, bank, custodian, trust company or other nominee or intermediary must contact such entity if it wishes to tender Notes in the Tender Offer (or to validly withdraw any such tender). None of the Company, the Dealer Manager, the Information & Tender Agent and any person who controls, or is a director, officer, employee or agent of such persons, or any affiliate of such persons, makes any recommendation as to whether Holders should participate in the Tender Offer.

OFFER AND DISTRIBUTION RESTRICTIONS

This announcement and the Offer to Purchase do not constitute an offer or an invitation to participate in the Tender Offer in any jurisdiction in which, or to any person to or from whom, it is unlawful to make such offer or invitation or for there to be such participation under applicable laws. The distribution of this announcement and the Offer to Purchase in certain jurisdictions may be restricted by law. Persons into whose possession this announcement or the Offer to Purchase comes are required by the Company, the Dealer Manager and the Information & Tender Agent to inform themselves about and to observe any such restrictions.

United Kingdom

The Offer to Purchase is only addressed to Holders where they would (if they were clients of the Company) be per se professional clients or per se eligible counterparties of the Company within the meaning of the rules of the Financial Conduct Authority ("FCA"). Neither the Offer to Purchase nor any other related documents or materials are addressed to or directed at any persons who would be retail clients within the meaning of the FCA rules and any such persons should not act or rely on them. Recipients of the Offer to Purchase and any other documents or materials relating to the Tender Offer should note that the Company is acting on its own account in relation to the Tender Offer and will not be responsible to any other person for providing the protections which would be afforded to clients of the Company or for providing advice in relation to the Tender Offer.

This announcement, the Offer to Purchase and any other documents and/or materials relating to the Tender Offer are not being made and this announcement, the Offer to Purchase and such documents and/or materials have not been approved by an authorized person for the purposes of section 21 of the Financial Services and Markets Act 2000, as amended. Accordingly, this announcement, the Offer to Purchase and such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of this announcement, the Offer to Purchase and such documents and/or materials as a financial promotion is only being made to persons outside the United Kingdom and to those persons in the United Kingdom falling within the definition of investment professionals (as defined by Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotion Order")) or persons who are within Article 43(2) of the Financial Promotion Order or any other persons to whom they may otherwise lawfully be communicated under the Financial Promotion Order (all such persons together being referred to as "relevant persons") and the transactions contemplated herein will be available only to, and engaged in, by relevant persons. Any person who is not a relevant person should not act on or rely on this announcement, the Offer to Purchase and any such other documents and/or materials in the United Kingdom.

France

This announcement, the Offer to Purchase and any other documents and/or materials relating to the Tender Offer may not be distributed in the Republic of France other than to qualified investors (investisseurs qualifiés) as defined in Article L.411-2 1° of the French Code monétaire et financier and only qualified investors (investisseurs qualifiés) are eligible to participate in the Tender Offer. The Tender Offer, this announcement, the Offer to Purchase and any other documents and/or materials relating to the Tender Offer have not been and will not be submitted for clearance to nor approved by the Autorité des marchés financier.

Italy

None of the Tender Offer, this announcement, the Offer to Purchase and any other documents or materials relating to the Tender Offer has been or will be submitted to the clearance procedure of the Commissione Nazionale per le Società e la Borsa ("CONSOB"), pursuant to Italian laws and regulations. The Tender Offer is being carried out in Italy as an exempted offer pursuant to article 101-bis, paragraph 3 bis of the

Legislative Decree No. 58 of February 24, 1998, as amended (the "Financial Services Act") and article 35-bis, paragraph 4 of CONSOB Regulation No. 11971 of May 14, 1999, as amended. Accordingly, Holders or beneficial owners of the Notes that are located in Italy can tender Notes through authorized persons (such as investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with the Financial Services Act, CONSOB Regulation No. 20307 of February 15, 2018, as amended from time to time, and Legislative Decree No. 385 of September 1, 1993, as amended) and in compliance with applicable laws and regulations or with requirements imposed by CONSOB or any other Italian authority.

General

This announcement is for informational purposes only and shall not constitute an offer to buy, a solicitation to buy or an offer to sell any securities. The Tender Offer is being made only pursuant to the Offer to Purchase and only in such jurisdictions as is permitted under applicable law. Please see the Offer to Purchase for certain important information on offer restrictions applicable to the Tender Offer.

- ends -

Investor contacts

Media Enquiries

Charles Reynolds +44 7811 121398
Smith+Nephew [email protected]

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day,

making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The term 'Smith+Nephew' is used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook

Smith+Nephew Forward-looking Statements

This announcement contains certain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related

investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organization to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; effects of AI use and deployment; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F for the year ended December 31, 2025 and interim financial statements on Form 6-K for the six months period ended June 27, 2026, which are available on the SEC's website at www. sec.gov and the Offer to Purchase, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. The Company can give no assurance that any goal or plan set forth in the Company's forward-looking statements will be achieved and readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Smith & Nephew Plc

NEW YORK--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, announced today that Laura Cockrill, Chief Financial Officer, and Ron Herrmann, Chief Commercial Officer and Executive Vice President of Americas and EMEA, will participate in a fireside chat at the 2026 Barclays Annual Global Financial Services Conference on Tuesday, Sept. 15, 2026, from 8:15 a.m. to 8:55 a.m. Eastern Time. A live webcast of this event will be accessib.

, /PRNewswire/ -- Academy Sports + Outdoors (the "Company") (Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, today announced its participation in the upcoming Goldman Sachs 33rd Annual Global Retailing Conference to be held Monday, September 14 to Tuesday, September 15, 2026. Chief Executive Officer, Steve Lawrence, and Chief Financial Officer, Carl Ford, will participate in a fireside chat that will be webcast live on September 15th, at 11:30 a.m. Eastern Time. The live webcast can be accessed through this link:  https://cc.webcasts.com/gold006/091426a_js/?entity=30_DHR2B7S

A live and replay webcast (for 30 days) of the fireside chat will be made available on the Company's investor relations website at investors.academy.com.

About Academy Sports + Outdoors
Academy is a leading full-line sporting goods and outdoor recreation retailer in the United States. Originally founded in 1938 as a family business in Texas, Academy has grown to more than 300 stores across 21 states and counting. Academy's mission is to provide "Fun for All" and Academy fulfills this mission with a localized merchandising strategy and value proposition that strongly connects with a broad range of consumers. Academy's product assortment focuses on key categories of outdoor, apparel, sports & recreation and footwear through both leading national brands and a portfolio of private label brands. For more information, visit www.academy.com.

Investor inquiries:
Dan Aldridge, Vice President of Investor Relations
832.739.4102
[email protected]

Media inquiries:
Meredith Klein, Vice President of Communications
346.826.6615
[email protected]

SOURCE Academy Sports + Outdoors

NetScout Systems (NTCT - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for NetScout basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for NetScout imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for NetScoutThis provider of products that gauge network performance is expected to earn $2.74 per share for the fiscal year ending March 2027, which represents no year-over-year change.

Analysts have been steadily raising their estimates for NetScout. Over the past three months, the Zacks Consensus Estimate for the company has increased 4.4%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of NetScout to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Public event brings together a radiologist, urologist and robotic surgeon, and a prostate cancer survivor for an informative conversation and live Q&A about prostate cancer screening, diagnosis and treatment  | Source: RadNet, Inc.

LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 442 outpatient imaging centers and a premier developer of radiology digital health solutions, today announced it will host a free webinar for patients and the general public on Saturday, September 19, 2026, in support of Prostate Cancer Awareness Month.

Titled “Let’s Talk About It: Prostate Cancer: Your Questions Answered,” the webinar brings together a radiologist, urologist and robotic surgeon, and a prostate cancer survivor for a candid discussion about prostate cancer risk, screening, diagnosis, treatment and life after cancer. Attendees will also have the opportunity to submit questions during a live question-and-answer session.

Besides skin cancer, prostate cancer is the most commonly diagnosed cancer among American men. Approximately one in eight men will be diagnosed during his lifetime, and an estimated 333,830 new cases will be diagnosed in the United States in 2026.1 Although prostate and breast cancer have similar incidence and mortality rates in the United States, only 37% of men age 50 and older reported having a PSA test in the past year, compared with 80% of women ages 50 to 74 who were up to date with mammography.2 Age, family history and certain inherited genetic variants can increase a man’s risk of prostate cancer. For men with a strong family history, including two or more first-degree relatives diagnosed with prostate cancer, the relative risk may be four times higher.3

The September 19th webinar will help patients and families better understand these risks, what may happen following an elevated prostate-specific antigen (PSA) test and how advances in prostate MRI and other imaging technologies are informing diagnosis and treatment planning. The webinar also will explore how prostate MRI can help physicians identify suspicious areas that may require further evaluation and support more targeted biopsy decisions for patients with elevated PSA levels.4

The panelists include:

Robert Princenthal, MD, Medical Director of Prostate Imaging at RadNet, will discuss the importance of early detection, the role of prostate MRI and other imaging tools beyond the PSA test and recent advances in MRI, artificial intelligence and prostate cancer imaging.David Josephson, MD, urologist and robotic surgeon at Tower Urology in Los Angeles, will explain what patients can expect after an elevated PSA result and how physicians evaluate treatment options, from active surveillance to surgery and other therapies. He will also address prostate health at different ages, including risk factors, family history and genetics, and when men should begin speaking with their physicians about screening.Barry Katz, prostate cancer survivor, will share his personal experience, including how RadNet’s Enhanced Prostate Screening, which combines prostate MRI with AI, helped detect his cancer. He will also discuss the lessons he learned along the way and his advice for men and families navigating prostate cancer. “Too often, men wait until there is a concern to start thinking about prostate health,” said Robert Princenthal, MD, Medical Director of Prostate Imaging, RadNet. “By making information more accessible, we can help men ask the right questions sooner and better understand when it is time to take action. My hope is that everyone who joins us leaves more confident about their next steps and is motivated to start more conversations about prostate health."

Event Details
The webinar is free to attend and open to all.

Date: Saturday, September 19, 2026Time: 10-11 a.m. PDT // 1-2 p.m. EDTRegister: www.radnet.com/webinar About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 12,000 team members. Learn more at radnet.com. 

These presentations are provided for educational and informational purposes only and do not constitute medical advice, diagnosis or treatment recommendations. Clinical decisions should be based on the independent judgment of qualified healthcare professionals, taking into account the specific circumstances of each patient.

RadNet Media Contact 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
[email protected]

References

“Key Statistics for Prostate Cancer.” American Cancer Society. January 2026, https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html.“Cancer Prevention & Early Detection Facts & Figures 2025-2026.” American Cancer Society. 2025, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/2025-cped-files/cped-cff-2025-2026.pdf.Wei JT, et al., “Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.” The Journal of Urology. October 2023, https://www.auajournals.org/doi/10.1097/JU.0000000000003491.“Prostate Cancer Screening (PDQ®)–Health Professional Version.” National Cancer Institute. April 2025, https://www.cancer.gov/types/prostate/hp/prostate-screening-pdq.

RadNet.com

CaliberCos (NASDAQ:CWD – Get Free Report) and Apollo Global Management (NYSE:APO – Get Free Report) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings This is a summary of current recommendations for CaliberCos and Apollo Global Management, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CaliberCos 1 1 0 0 1.50 Apollo Global Management 0 4 12 1 2.82 Apollo Global Management has a consensus price target of $152.15, suggesting a potential upside of 15.34%. Given Apollo Global Management’s stronger consensus rating and higher possible upside, analysts clearly believe Apollo Global Management is more favorable than CaliberCos.

Profitability This table compares CaliberCos and Apollo Global Management’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets CaliberCos -117.34% -75.44% -13.87% Apollo Global Management 5.22% 14.01% 1.18% Insider & Institutional Ownership 4.1% of CaliberCos shares are owned by institutional investors. Comparatively, 77.1% of Apollo Global Management shares are owned by institutional investors. 8.3% of CaliberCos shares are owned by company insiders. Comparatively, 8.3% of Apollo Global Management shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation This table compares CaliberCos and Apollo Global Management”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CaliberCos $20.10 million 0.27 -$21.80 million ($3.79) -0.14 Apollo Global Management $32.05 billion 2.43 $3.49 billion $2.73 48.32 Apollo Global Management has higher revenue and earnings than CaliberCos. CaliberCos is trading at a lower price-to-earnings ratio than Apollo Global Management, indicating that it is currently the more affordable of the two stocks.

Summary Apollo Global Management beats CaliberCos on 13 of the 14 factors compared between the two stocks.

About CaliberCos (Get Free Report)

Caliber (NASDAQ: CWD) is a vertically integrated alternative asset management firm whose purpose is to build generational wealth for investors seeking to access opportunities in middle-market assets. Caliber differentiates itself by creating, managing, and servicing proprietary products, including middle-market investment funds, private syndications, and direct investments which are managed by our in-house asset services group. Our funds include investment vehicles focused primarily on real estate, private equity, and debt facilities. Additional information can be found at Caliberco.com and CaliberFunds.co.

(Get Free Report)

Apollo Global Management, Inc. is a private equity firm specializing in investments in credit, private equity, infrastructure, secondaries and real estate markets. The firm prefers to invest in private and public markets. The firm’s private equity investments include traditional buyouts, recapitalization, distressed buyouts and debt investments in real estate, corporate partner buyouts, distressed asset, corporate carve-outs, middle market, growth, venture capital, turnaround, bridge, corporate restructuring, special situation, acquisition, and industry consolidation transactions. For credit strategies, the firm focuses to invest in multi-sector credit, semi-liquid credit, direct lending, first lien, unitranche, whole loans and private credit. The firm provides its services to endowment and sovereign wealth funds, as well as other institutional and individual investors. It manages client focused portfolios. The firm launches and manages hedge funds for its clients. It also manages real estate funds and private equity funds for its clients. The firm invests in the fixed income and alternative investment markets across the globe. Its fixed income investments include income-oriented senior loans, bonds, collateralized loan obligations, structured credit, opportunistic credit, non-performing loans, distressed debt, mezzanine debt, and value oriented fixed income securities. The firm seeks to invest in chemicals, commodities, consumer and retail, oil and gas, metals, mining, agriculture, commodities, distribution and transportation, financial and business services, manufacturing and industrial, media distribution, cable, entertainment and leisure, telecom, technology, natural resources, energy, packaging and materials, and satellite and wireless industries. It also focuses on clean energy, sustainable industry, climate solutions, energy transition, industrial decarbonization, sustainable mobility, sustainable resource use, and sustainable real estate. It seeks to invest in companies based in across Africa, Asia, North America with a focus on United States, Western Europe and Europe. It employs a combination of contrarian, value, and distressed strategies to make its investments. The firm seeks to make investments in the range of $75 million and $1500 million. The firm seeks to invest in companies with Enterprise value between $750 million to $2500 million. The firm conducts in-house research to create its investment portfolio. It seeks to acquire minority and majority positions in its portfolio companies. Apollo Global Management, Inc. was founded in 1990 and is headquartered in New York, New York with additional offices in North America, Asia, Africa and Europe.

Receive News & Ratings for CaliberCos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CaliberCos and related companies with MarketBeat.com's FREE daily email newsletter.

SEOUL, South Korea--(BUSINESS WIRE)--Ralph Lauren (NYSE:RL) today announced a partnership with the Korea National Cancer Center Foundation to establish The Ralph Lauren Center for Patient and Family Recovery at the National Cancer Center of Korea (NCC) in Goyang, South Korea, marking the first Ralph Lauren cancer center in Asia. Building on Ralph Lauren's longstanding support for cancer prevention and treatment efforts, the new center represents the next chapter in its commitment to expanding a.

Guidewire Software, Inc. (NYSE:GWRE) had one of the ugliest earnings reactions in software this quarter. The Guidewire stock drop reached as much as 20.8% during the day on Friday, September 5, 2026. Shares hit a low of $157.05 and later settled in the $160-$166 range.

That’s well below Thursday’s closing price of $202.86. As a result, the sell-off wiped out more than $2 billion in market value in a single session.

Yet the company topped Street estimates on both revenue and profit. Instead, investors zeroed in on a soft first-quarter guide. They also spotted early signs that the ARR growth story is cooling. This Guidewire stock drop fits a pattern seen across software earnings this season.

The Numbers Behind The Guidewire Stock DropGuidewire’s fiscal Q4 2026 results were announced on Thursday evening. Overall, they cleared the bar comfortably:

Adjusted EPS of $0.99 vs. the $0.93 consensusRevenue of $411.1 million vs. ~$402.7 million estimate, up 23% year-over-yearARR of $1.242 billion, up 19% year-over-year and above guidanceCloud ARR up 35% year-over-year, now 84% of total ARROperating income of $340 million, up 63% year-over-yearGross ARR attrition below 1.5% company-wideCEO Mike Rosenbaum made an optimistic statement and said that the transition to cloud technologies is proceeding in accordance with expectations. In particular, he noted an increase in margins and cash flow. He also mentioned PricingCenter’s new deal with Nationwide.

So Why Did The Guidewire Stock Drop Happen?The last quarter looked great on paper but investors were already thinking ahead to what comes next for Guidewire, and that’s where we have the worry.

Light Q1 FY27 revenue guide: According to Guidewire’s forecast, revenue in Q1 2027 amounted to 372-378 million dollars. This is ~3.3% lower than analysts’ forecasts. Consequently, this led to an immediate decrease in sales after business hours. ARR growth is decelerating: Full-year FY27 ARR guidance implies growth of ~18%. That’s down from 19% in FY26. According to management, part of this reflects normalizing attrition rates. License revenue headwind: Guidewire flagged a $46 million license revenue decline for FY27. This shows the ongoing shift toward subscription-based cloud contracts. Valuation And Macro PressureTwo more factors made things even worse:

Valuation left no room for error and heading into earnings, GWRE traded above a 120x trailing P/E. Therefore, a "beat and maintain" quarter wasn’t enough as Wall Street wanted "beat and raise". Macro crosswinds added pressure and a strong U.S. jobs report reignited debate over Fed rate policy. This weighed on high-multiple software names broadly, so there was no market cushion left for GWRE’s stumble. Wall Street’s Reaction Was Mixed, Not BearishNotably, analysts didn’t abandon the stock. and most kept bullish ratings. Still, they changed price targets to reflect the reset:

Oppenheimer kept "Outperform" and raised its target to $210 DA Davidson reiterated "Buy" with a $222 target Baird kept "Outperform" with a $235 target Goldman Sachs held "Buy" while cutting its target from $255 to $225 Overall, the Street consensus is a "Moderate Buy." In fact, average targets still imply solid upside from Friday’s price.
So what’s the takeaway? The deceleration looks real, but modest. Meanwhile, over half of next year’s net-new ARR is already under contract and also, record-low attrition suggests the core franchise stays durable.

The Bigger PictureGWRE now trades over 40% below its 52-week high of $272.60. Still, it remains well above its 52-week low of $102.30. The stock has logged nearly 40 moves greater than 5% this past year. Even so, Friday’s drop stands out. Ultimately, this Guidewire stock drop shows that “very good” guidance isn’t good enough for a stock priced for perfection. So is this a healthy reset? Or is it the first crack in an overheated growth story? That’s the question investors now face.

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Hledat v komentářích

Investiční doporučení

Výsledky společností - ČR

Výsledky společností - Svět

IPO, M&A

Týdenní přehledy

Detail - články  

09.09.2026 12:28

Rozvíjející se trhy zažívají mimořádně silné období díky globálním investicím do AI infrastruktury. Analytici letos zvýšili odhady zisků společností zahrnutých do indexu MSCI Emerging Markets o rekordních 65 %, což představuje nejrychlejší tempo růstu v historii sledování tohoto ukazatele.

Pokračování článku je dostupné jen klientům placených služeb Patria Plus / Investor Plus případně uživatelům platformy Patria Direct. Pokud jste klientem těchto služeb, potom je nutné se Přihlásit.

V rámci placeného informačního servisu získáte přístup ke kompletnímu zpravodajství www.patria.cz bez jakýchkoliv omezení. Veškeré zprávy, komentáře a horké zprávy jsou zobrazovány terminálovou metodou (bez nutnosti obnovovat stránku) bez zpoždění a v plné verzi.

Nejen zpravodajství, ale i další služby získáte v Patria Plus / Investor Plus - sms a e-mailové zpravodajství, data z finančních trhů v reálném čase, kompletní analytický servis, rozsáhlé databáze časových řad ke stažení, prognózy vývoje a valuace, ekonomické fundamenty, nástroje a kalkulátory... více

Tagy: emerging markets, MSCI, Výhled, Zisky, rozvíjející se ekonomiky
Reklama

Na tomto místě můžete zahájit diskusi. Zatím nebyl zadán žádný názor. Do diskuse mohou přispívat pouze přihlášení uživatelé (Přihlásit). Pokud nemáte účet, na který byste se mohli přihlásit, registrujte se zde.

Aktuální komentáře

09.09.2026 12:28Rozvíjející se trhy těží z AI boomu. Odhady zisků v indexu MSCI EM rostou nejrychleji v historii   11:44ČEZ získal povolení k použití jaderného paliva od Westinghouse v Temelíně 11:14Ropa za 100 a strach z inflace drží sentiment dole   10:37Trénoval modely pro OpenAI i Anthropic, teď opouští obor a varuje před podceňováním rizik 9:23Bessent vyhlašuje válku spekulantům, chce zastavit útoky na jen 8:58Rozbřesk: Minimální mzda výrazně vzroste, jaké budou dopady do české ekonomiky? 8:37USA přitvrzují v obchodní válce s Kanadou, ropa je už na 99 dolarech, Evropa otevře poklesem   8:35EU a Kanada chystají strategické partnerství. Chtějí posílit obchod, obranu i nezávislost na velmocích 6:03ASML dostalo od klíčových zákazníků zelenou pro novou generaci litografických strojů 08.09.2026 22:01Akcie i dluhopisy oslabily, růst ropy zvýšil obavy z dalšího růstu sazeb   17:06Do popředí vystupuje paradox na zlatu 15:43Starteepo vyzvala Xerox k odemčení hodnoty finanční divize 13:29Tesla rozjíždí Cybercabs, přichází čínská automobilová expanze ve Spojených státech 11:57Po klidném létě může přijít bouřlivý podzim. Trhy čeká test inflace, dluhu i geopolitiky   11:56Volkswagen zvažuje prodej Ducati. Ikonická motocyklová značka může pomoci financovat restrukturalizaci 11:35Výnosy dluhopisů stoupají, akcie jsou pod tlakem. Není to jen o ropě a obavách z inflace   10:53Evropský AI šampion Mistral získal rekordní finance a míří mezi technologickou elitu 10:15Neúspěchy farmaceutických gigantů: Novartis zklamal v klíčové zkoušce, Novo Nordisk ruší studie 8:54Jen sílí, měď láme rekordy a ropa míří ke 100 dolarům   8:53Rozbřesk: Průmysl jede dál, noví tahouni na obzoru?
Reklama

Související komentáře

Nejčtenější zprávy dne

Nejčtenější zprávy týdne

Nejdiskutovanější zprávy týdne

Kalendář událostí

ČasUdálost PL - Jednání NBP, základní sazba 3:30Čína - CPI, y/y

-

Bringing biocompatible, clinically effective skincare to communities across Mexico and Canada

LOS ANGELES--(BUSINESS WIRE)--Today, Naturium, a brand from e.l.f. Beauty (NYSE: ELF), announced its expansion with Sephora across Canada and Mexico, bringing its biocompatible, clinically effective skincare to new consumers across North America. Delivering affordable luxury for head-to-toe skincare, the brand makes its official debut in Mexico exclusively in Sephora Mexico stores and on Sephora.com.mx, while broadening its Canadian retail footprint online and in Sephora Canada stores nationwide.

Since its launch in 2019, Naturium has built a loyal, community-driven following based on a simple idea: effective skincare should be easy to understand and incorporate into everyday life. The Sephora expansion marks the next step in the brand’s continued growth, bringing its mission of ‘skin love for everyone’ to more consumers across North America. With the addition of these two markets, Naturium is now available in six regions globally.

“To see Naturium continue to grow and reach new markets is incredibly meaningful to us. We have been working to expand Naturium’s retail presence internationally and getting the best of Naturium into more hands,” said Suzanne Pengelly, President of Naturium. “We’ve built Naturium around products people genuinely love making part of their everyday routines, and we can’t wait for even more consumers to discover them.”

“We’re very happy to welcome Naturium to Sephora Mexico and add to our portfolio a brand that combines innovation, clinical efficacy, and an accessible approach to skincare,” said Mauricio Padilla, CEO of Sephora Mexico. “We’re confident its proposition will strongly resonate with our clients, and we’re excited to be its exclusive retail destination in Mexico.”

At Sephora Canada and Sephora Mexico, consumers can find an assortment of Naturium’s bestselling skincare and body care formulas, including:

Glow Getter Multi-Oil Hydrating Body Wash – Best-selling vanilla coconut body wash that delivers a multi-oil glow from head to toe. Glow Getter Multi-Oil Body Butter – Luxurious, vanilla coconut, fast absorbing body butter includes 81% multi-oil complex for glowing, replenished and firmer-looking skin. Multi-Peptide Moisturizer – Clinically-proven moisturizer that improves wrinkles & hydration in 100% of consumers and firmness in 97% of consumers. Vitamin C Complex Serum – Gold stabilized Vitamin C delivered in a biocompatible, ph-balance that is suitable for all skin types. To celebrate its launch in Sephora Canada, Naturium is rolling out a brand campaign across Canada featuring its Canadian community and their love of skincare, including partnerships with creators that are long-time brand fans, and have championed Naturium for years. The brand will also host an experiential activation on September 12 in Toronto at The Well, where guests can enjoy a special photobooth experience, product education, customized skincare routines, and take home some of the brand's most loved products.

Beginning September 9, Naturium will be available online at sephora.com/ca/en/ and in Sephora Canada stores nationwide. In Mexico, Naturium will be available exclusively at Sephora Mexico stores and on Sephora.com.mx.

About Naturium
Founded in 2019, Naturium brings the science of consistent skincare to every one, every where, every day. The brand's biocompatible and dermatologist-tested formulas work with individual skin's biology from head to toe, blending natural botanicals with potent actives for clinically effective results at an accessible price point. Naturium has pioneered facial and body care innovations. Naturium is clean, vegan, paraben-free, and double-certified by Leaping Bunny and PETA as cruelty-free. Acquired by e.l.f. Beauty (NYSE: ELF) in 2023, the brand is available at naturium.com and both in-store and online at Target and Ulta in the U.S.

About Sephora
Sephora is the world’s leading global prestige beauty retail brand. With 55,000 passionate employees operating in 37 markets, Sephora connects customers and beauty brands within the world’s most trusted and dynamic beauty community. We serve a highly engaged community of hundreds of millions of beauty followers across our global omnichannel network of more than 3,400 stores and iconic flagships, and our e-commerce and digital platforms, offering personalized and immersive seamless experiences across every touchpoint. With our curation of more than 500 brands and our own label, Sephora Collection, we offer the most unique and diverse range of prestige beauty products, tailored to our customers’ needs from fragrance to make-up, haircare, skincare and beyond, as we constantly reimagine the world of prestige beauty. Since SEPHORA’s inception in 1969 in Limoges, France, and as part of the LVMH Group since 1997, the brand has been disrupting the prestige beauty retail industry. Today, they continue to break with convention to drive their mission: champion a world of inspiration and inclusion where everyone can celebrate their beauty. For more information, visit www.sephora.com.

More News From Naturium

Back to Newsroom

Partnership Expands Access to the BioCode® MDx-3000 System for Hospitals and Reference Laboratories

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode today announced a distribution agreement with Henry Schein, a leading provider of healthcare products and services, to expand the availability of its BioCode® MDx-3000 System and comprehensive molecular diagnostics menu.

"Helping broaden access to advanced molecular diagnostic capabilities"

Share The BioCode® MDx-3000 is an automated, high-throughput multiplex molecular diagnostic platform designed to support high-complexity clinical laboratories. Its testing menu includes upper respiratory and gastrointestinal infection panels, with a customizable menu option, enabling laboratories to deliver accurate, cost-effective, and efficient molecular diagnostic testing.

Through this agreement, Henry Schein will distribute the MDx-3000 System and its associated assays to hospitals, health systems, and reference laboratories nationwide, helping broaden access to advanced molecular diagnostic capabilities.

"Applied BioCode is excited to partner with Henry Schein as we continue expanding our presence in hospitals and reference laboratories across the United States," said Jim Leigh, Sr. Vice President of Sales. "Henry Schein's extensive laboratory distribution network makes them an ideal partner to help bring our innovative molecular diagnostic solutions to more clinical laboratories."

Applied BioCode remains committed to advancing molecular diagnostics through innovative technologies that improve laboratory workflows and deliver accurate, reliable, and actionable results for healthcare providers and patients.

About Applied BioCode

Applied BioCode is a leading provider of molecular diagnostic solutions, focused on developing innovative technologies that empower clinical laboratories, improve operational efficiency, and enhance patient care.

To learn more about Applied BioCode's molecular diagnostic solutions, visit:

https://www.apbiocode.com/products/.

Investors interested in Financial - Investment Management stocks are likely familiar with Patria Investments (PAX - Free Report) and KKR & Co. Inc. (KKR - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Patria Investments and KKR & Co. Inc. are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. Investors should feel comfortable knowing that PAX likely has seen a stronger improvement to its earnings outlook than KKR has recently. However, value investors will care about much more than just this.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.

PAX currently has a forward P/E ratio of 8.10, while KKR has a forward P/E of 16.49. We also note that PAX has a PEG ratio of 0.76. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. KKR currently has a PEG ratio of 0.88.

Another notable valuation metric for PAX is its P/B ratio of 1.19. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, KKR has a P/B of 1.29.

Based on these metrics and many more, PAX holds a Value grade of A, while KKR has a Value grade of D.

PAX has seen stronger estimate revision activity and sports more attractive valuation metrics than KKR, so it seems like value investors will conclude that PAX is the superior option right now.

Key Takeaways NuFormer is expanding across credit, customer service and growth campaigns at NU.NU's $39.4 billion credit portfolio grew 37%, while risk-adjusted NIM rose to 12.4%.NuFormer now runs faster and cheaper, with AI agents handling over 60% of Brazil support chats. Nu Holdings Ltd. (NU - Free Report) is putting artificial intelligence deeper into its operating model, with NuFormer central to underwriting, customer service and growth. The company said the model draws on more than a decade of transaction history across over 100 million customers in Brazil, Mexico and Colombia, giving it a large base of financial behavior data.

NuFormer has become faster and cheaper to run. Its latest generation quadrupled its context length, training speed and inference speed while lowering production costs. The model is used for credit cards in Brazil and Mexico and unsecured lending in Brazil, while SME credit cards and Colombian cards are being tested.

The push matters because credit remains a major earnings driver. NU ended the second quarter of 2026 with a $39.4 billion credit portfolio, up 37% year over year. Risk-adjusted net interest margin rose to 12.4% from 9.5% in the first quarter, helped by stronger credit income and a lower cost of credit.

AI is also moving beyond underwriting. Generative AI agents now handle more than 60% of customer support conversations in Brazil, with ratings at or above human levels. NuFormer is also being used to target growth campaigns, with more than 100 campaigns already run using the platform.

The financial backdrop gives NU room to invest. Second-quarter 2026 gross revenues reached $5.9 billion, up 39% year over year, while net income hit $1.1 billion. The company served 139 million customers, ARPAC reached $17 and the efficiency ratio stood at 19.5%, showing that AI investment is being layered onto a scaled platform.

How Are Itau Unibanco & MercadoLibre Compete?Itau Unibanco (ITUB - Free Report) , a major Brazilian banking rival to Nu Holdings, is embedding generative AI across customer service, business banking and payments. In June 2026, Itau Unibanco partnered with Google to expand Gemini access and AI training for SMEs. By late July 2026, its ia.i assistant was already available to approximately 300,000 Superapp users.

MercadoLibre (MELI - Free Report) , via its Mercado Pago platform, competes with Nu Holdings across Latin American payments, credit and digital financial services. The company uses AI and machine learning in credit scoring, customer service, advertising and marketplace search. In second-quarter 2026, MELI completed the rollout of an AI powered search architecture across its five largest sites. In second-quarter 2026, Mercado Pago reached 88 million monthly active users.

NU’s Price Performance, Valuation and EstimatesShares of NU have gained 29.4% in the past three months, outperforming the broader industry and the S&P 500 Index.

Image Source: Zacks Investment Research

From a valuation standpoint, NU trades at a forward price-to-earnings ratio of 14.38X, well above the industry’s 11.55X. It carries a Value Score D.

Image Source: Zacks Investment Research

NU’s estimates have increased 3 cents over the past month. The Zacks Consensus Estimate for full-year 2026 EPS is pegged at 86 cents.

Image Source: Zacks Investment Research

NU stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DES MOINES, Iowa, Sept. 8, 2026 /PRNewswire/ -- F&G Annuities & Life, Inc. (NYSE: FG) (F&G) today announced that Conor Murphy, CEO & President, and Michael Bailey, EVP, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Financial Services Conference on Monday, September 14, 2026 at 9:45 am Eastern Time.

1.75K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MPLX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

EU regulators are preparing to warn Hong Kong-listed mining and metals company MMG (1208.HK) ​over its plan to buy Anglo American's (AAL.L) Brazilian nickel business ‌because of competition concerns, three people familiar with the matter said.

The step reflects mounting European Union concern about the bloc's reliance on China for critical ​minerals vital to defence, technology and renewable energy and Beijing's ​use of export control measures on critical mineral supplies.

The ⁠European Commission, which acts as the EU competition enforcer, is ​preparing to send out this month what is known as a ​statement of objections or a charge sheet, setting out the concerns that will need to be addressed for the deal to be cleared, the people said. ​They spoke on condition of anonymity because the matter is ​not yet public.

MMG could stave off the charge sheet by offering remedies, but ‌this ⁠is regarded as unlikely, one of the people said.

The EU antitrust watchdog and MMG declined to comment. Anglo American reiterated comments issued two weeks ago.

"The evidence we've provided demonstrates that this transaction poses ​no competition concerns ​to the EU ⁠market and should be approved unconditionally," it said in a statement to Reuters.

"Over the past year, ​the market has benefited from a significant structural expansion ​of ⁠FeNi supply from a number of producers, whilst European customers have shown how readily they can switch between their various suppliers," it said.

The ⁠Commission ​in November said the deal could enable MMG ​to divert ferronickel from Europe and undermine the competitiveness of European stainless steel production.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors of the November 2, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.

Should You Join The Hims Class Action Lawsuit:

Do you, or did you, own shares of Hims, Inc. (NYSE: HIMS)?Did you purchase your shares between August 4, 2025 and July 29, 2026, inclusive?Did you lose money in your investment in Hims, Inc.?
What To Do Next:

Investors are encouraged to act promptly and submit a form at Hims & Hers Health, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].

If you wish to serve as lead plaintiff for the Class, you must file papers by November 2, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About The Lawsuit:

A lawsuit was filed on behalf of investors (the “Class”) who purchased or acquired the securities of Hims between August 4, 2025 and July 29, 2026, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.

The lawsuit alleges that defendants made materially false and misleading statements and omissions regarding the Company’s business operations, growth prospects, and financial stability. As a result of these alleged misrepresentations, Hims securities traded at artificially inflated prices during the Class Period. When the truth was disclosed, investors allegedly suffered significant losses.

About Bernstein Liebhard:

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
[email protected]

LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: August 4, 2025 to July 29, 2026

DEADLINE: November 2, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Hims & Hers provided customer health data to third-party advertising platforms. The Company’s treatment practices were likely to result in heightened regulatory scrutiny. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Hims & Hers, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

 Schall, Brown & Schwartz LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Hims between August 4, 2025 and July 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - September 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims" or the "Company") (NASDAQ: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company shared consumers' health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 29, 2026, during market hours, the Federal Trade Commission announced it had filed a lawsuit against Hims "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." On this news, Hims's stock price fell $4.32, or 14.73%, to close at $25.00 per share on July 29, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Hims's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Hims class action, go to www.faruqilaw.com/HIMS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Hims Securities Class Action Lawsuit:

What is the Hims securities fraud lawsuit about?

Faruqi & Faruqi, LLP has filed a securities class action lawsuit alleging that Hims & Hers Health, Inc. (NASDAQ: HIMS) made materially false and misleading statements to investors during the Class Period. The complaint alleges that the Company shared consumers' sensitive health information with third-party advertising platforms despite representing that its services maintain consumer privacy, and that the Company allegedly charged consumers for prescriptions almost immediately after intake form submission while telling consumers they would first be able to consult with a medical provider. The lawsuit further alleges that this conduct subjected Hims to regulatory scrutiny and made the Company reasonably likely to incur fees and penalties. On July 29, 2026, the Federal Trade Commission announced it had filed a lawsuit against Hims alleging these practices, and on that news Hims's stock price allegedly fell $4.32, or approximately 14.73%, to close at $25.00 per share on unusually heavy trading volume. As a result of the foregoing, the complaint alleges that Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. (NASDAQ: HIMS) on the NASDAQ exchange between August 4, 2025 and July 29, 2026, inclusive, may be eligible to participate in this class action lawsuit. Eligibility to participate in any potential recovery is not limited to investors who seek appointment as lead plaintiff; any investor who purchased Hims securities during the Class Period may be a class member. Eligible investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Investors with questions about their eligibility may wish to consult with counsel to better understand their rights and options in connection with this litigation.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who serves on behalf of all class members and plays an active role in directing the litigation, including working with counsel on case strategy and settlement decisions. Any investor who purchased Hims securities during the Class Period and suffered a loss may move the court for appointment as lead plaintiff, provided that motion is filed no later than November 2, 2026. Courts typically appoint the investor or group of investors with the largest financial interest in the litigation who also satisfy the requirements of Federal Rule of Civil Procedure 23 as lead plaintiff. Importantly, an investor need not seek appointment as lead plaintiff in order to participate in or share in any recovery that may result from the litigation. Investors who do not seek lead plaintiff status retain the right to remain members of the class and benefit from any judgment or settlement.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Hims securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313376

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

San Francisco, California--(Newsfile Corp. - September 8, 2026) - Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct.

Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now.

Class Period: Aug. 4, 2025 - July 29, 2026
Lead Plaintiff Deadline: Nov. 2, 2026
Visit Hims Investigation Page: www.hbsslaw.com/hims
Direct Contact Email: [email protected]
Firm Telephone: 844-916-0895

Hims & Hers Health ($HIMS) Securities Class Action

The lawsuit is focused on the propriety of Hims' repeated assurances that "[w]e have developed and maintain policies and procedures with respect to health information and personal information that we use or disclose in connection with our operations, including the adoption of administrative, physical, and technical safeguards to protect such information."

The complaint alleges that Hims: (1) shared consumers' health information with third-party advertising platforms; (2) charges consumers for prescriptions almost immediately after they submit intake forms, despite telling them that they will be able to consult with a medical provider to find a treatment that is "right for them[;]" and (3) as a result, would be subject to heightened regulatory scrutiny and likely to incur fees and penalties.

What Drove the $HIMS July 29, 2026 Stock Crash? The FTC and State Lawsuit Breakdown

The securities class action cites the July 29, 2026 federal complaint filed against Hims by the FTC-alongside co-plaintiffs the State of Utah and the County of Los Angeles (representing California).

After an extensive investigation by the Commission, it contends that Hims engaged in:

Deceptive Health Data Sharing: Despite extensive marketing campaigns emphasizing strict privacy, discreet telehealth consultations, and data protection, the complaint alleges that Hims surreptitiously shared sensitive user medical conditions and personal health data with third-party advertising giants, including Meta Platforms (Facebook) and Snap, via embedded tracking pixels and customer list matching. Subscription Billing & Cancellation Barriers (ROSCA Violations): The lawsuit accuses Hims of violating the Restore Online Shoppers' Confidence Act (ROSCA) by enrolling consumers in recurring subscription models without informed consent. According to regulators, consumers were billed for prescriptions almost immediately upon completing an intake form-long before receiving any consultation with a medical provider-while facing dark patterns and hidden cancellation options designed to prevent subscription termination.The market swiftly reacted, sending the price of Hims shares down $4.32 (-14.7%) and erasing over $970 million from the company's market capitalization in a single day.

"We're focused on whether Hims may have intentionally misled investors about its business practices, including the adequacy of its internal controls, and financial ramifications of the alleged misconduct," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in HIMS and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding HIMS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313516

Source: Hagens Berman Sobol Shapiro LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us